Skip to main content
SpringerLink
Log in
Book cover

Psoriasis and Psoriatic Arthritis pp 133–184Cite as

Psoriasis

  • Chapter

  • 1380 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   159.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akers WA (1980) Risks of unoccluded topical steroids in clinical trials. Arch Dermatol 116: 786–788

    Article  PubMed  CAS  Google Scholar 

  2. Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 14: 436–441

    Article  PubMed  CAS  Google Scholar 

  3. Beerman H, Kulchar GV, Pillbury DM, et al. (1935) Dioxyanthranol 1–8 as a substitute for chrysarobin. JAMA 104: 26–29

    CAS  Google Scholar 

  4. Behrens S, Grundmann-Kollmann M, Peter RU, Kerscher M (1999) Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. Br J Dermatol 141: 177

    Article  PubMed  CAS  Google Scholar 

  5. Behrens S, Grundmann-Kollmann M, Schiener R, Peter RU, Kerscher M (2000) Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 42: 493–495

    Article  PubMed  CAS  Google Scholar 

  6. Bernhard J, Whitmore C, Guzzo C, Kantor I, Kalb RE, Ellis C, Urbach F, Schwartzel EH, Gibson JR (1991) Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol 25: 1170–1174

    PubMed  CAS  Google Scholar 

  7. Berth-Jones J, Chu AC, Dodd WA, et al. (1992) A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 127: 266–271

    Article  PubMed  CAS  Google Scholar 

  8. Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE (1993) Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 129: 411–414

    Article  PubMed  CAS  Google Scholar 

  9. Besse JC, Bass AD (1966) Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J Pharmacol Exp Ther 154: 224–238

    PubMed  CAS  Google Scholar 

  10. Binderup L, Bramm E (1988) Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37: 889–895

    Article  PubMed  CAS  Google Scholar 

  11. Blum G, Yawalkar S (1991) A comparative, multicenter, double-blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized, plaque psoriasis. J Am Acad Dermatol 25: 1153–1156

    PubMed  CAS  Google Scholar 

  12. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119: 1198–1208

    PubMed  CAS  Google Scholar 

  13. Bourke JF, Berth-Jones J, Hutchinson PE (1993) Hypercalcaemia with topical calcipotriol. BMJ 306: 1344–1345

    PubMed  CAS  Google Scholar 

  14. Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE (1993) High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 129: 74–76

    Article  PubMed  CAS  Google Scholar 

  15. Bourke JF, Iqbal SJ, Hutchinson PE (1996) Vitamin D analogues in psoriasis: effects on systemic calcium homeostasis. Br J Dermatol 135: 347–354

    Article  PubMed  CAS  Google Scholar 

  16. Bourke JF, Mumford R, Whittaker P, Iqbal SJ, Le Van LW, Trevellyan A, Hutchinson PE (1997) The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 37: 929–934

    Article  PubMed  CAS  Google Scholar 

  17. Bowman PH, Maloney JE, Koo JY (2002) Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 46: 907–913

    Article  PubMed  Google Scholar 

  18. Bruce S, Epinette WW, Funicella T, et al. (1994) Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 31: 755–759

    PubMed  CAS  Google Scholar 

  19. Carruthers JA, August PJ, Staughton RCD (1975) Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J 4: 203

    Article  PubMed  CAS  Google Scholar 

  20. Chandraratna RA (1996) Tazarotene — first of a new generation of receptor-selective retinoids. Br J Dermatol 135Suppl 49: 18–25

    Article  PubMed  CAS  Google Scholar 

  21. Chandraratna RA (1997) Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 37: S12–17

    Article  PubMed  CAS  Google Scholar 

  22. Comaish JS (1981) Tar and related compounds in the therapy of psoriasis. Arch Dermatol 92: 56–58

    Article  Google Scholar 

  23. Cornell RC, Stoughton RB (1985) Correlation of the vasoconstrictive assay and clinical activity in psoriasis. Arch Dermatol 121: 63–67

    Article  PubMed  CAS  Google Scholar 

  24. Cunliffe WJ, Berth-Jones J, Claudy A, et al. (1992) Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 26: 736–743

    PubMed  CAS  Google Scholar 

  25. Dahl MGC (1985) Hazards of topical steroid therapy. Adverse Drug Reaction Bull 115: 428–431

    Article  Google Scholar 

  26. DeGroot AC, Nater JP (1981) Contact allergy to dithranol. Contact Dermatitis 7: 5–8

    Article  CAS  ISI  Google Scholar 

  27. de Jong EM, Mork NJ, Seijger MM, et al. (1993) The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 148: 318–325

    Article  Google Scholar 

  28. De Rie MA, Di Nuzzo S, Brands S, Hansen AB, Bos JD (2000) Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema. Br J Dermatol 142: 1160–1165

    Article  PubMed  Google Scholar 

  29. Dooms-Goossens AE, Degreef HJ, Marien KJ, Coopman SA (1989) Contact allergy to corticosteroids: a frequently missed diagnosis? J Am Acad Dermatol 21: 538–543

    PubMed  CAS  Google Scholar 

  30. Douglas WS, Poulin Y, Decroix J, et al. (2002) A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 82: 131–135

    Article  PubMed  CAS  Google Scholar 

  31. Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS (1989) Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol 20: 748–754

    Article  PubMed  CAS  Google Scholar 

  32. Dubertret L, Wallach D, Souteyrand P, et al. (1992) Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 27: 983–988

    PubMed  CAS  Google Scholar 

  33. Duvic M, Asano AT, Hager C, Mays S (1998) The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 39: S129–133

    Article  PubMed  CAS  Google Scholar 

  34. du Vivier A, Stoughton RB (1975) Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 111: 581–583

    Article  PubMed  Google Scholar 

  35. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdulla SA (2000) Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 20: 65–68

    PubMed  CAS  Google Scholar 

  36. Eells LD, Wolff JM, Garloff J, et al. (1984) Comparison of suberythromogenic and maximally aggressive ultraviolet B therapy for psoriasis. J Am Acad Dermatol 11: 105–110

    Article  PubMed  CAS  Google Scholar 

  37. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, Sefton J, Duvic M (1994) Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 30: 581–590

    PubMed  CAS  Google Scholar 

  38. Feldman RJ, Maibach HI (1967) Regional variation in percutaneous penetration of 14 C cortisol in man. J Invest Dermatol 48: 181–183

    Google Scholar 

  39. Fisher AA, Pascher F, Kanoff NB (1971) Allergic contact dermatitis due to ingredients of vehicles. A “vehicle tray” for patch testing. Arch Dermatol 104: 286–290

    Article  PubMed  CAS  Google Scholar 

  40. Fisher LB, Maibach HI (1971) The effect of corticosteroids on human epidermal mitotic activity. Arch Dermatol 103: 39–44

    Article  PubMed  CAS  Google Scholar 

  41. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS (1999) Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 38: 628–632

    Article  PubMed  CAS  Google Scholar 

  42. Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: a randomized double-blind placebo study in severe psoriasis. Eur J Dermatol 3: 351–354

    Google Scholar 

  43. Freeman AK, Linowski GJ, Brady C, et al. (2003) Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 48: 564–568

    Article  PubMed  Google Scholar 

  44. Gammon WR, Krueger GG, Van Scott EJ, et al. (1987) Intermittent short courses of clobetasol propionate ointment 0.05% in the treatment of psoriasis. Curr Ther Res 42: 419–427

    Google Scholar 

  45. Georgiou S, Tsambaos D (1999) Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol 79: 86

    Article  PubMed  CAS  Google Scholar 

  46. Goeckerman WH (1925) Treatment of psoriasis. Northwest Med 24: 229–231

    Google Scholar 

  47. Goldberg B, Hartdegen R, Presbury D, Smith EH, Yawalkar S (1991) A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 25: 1145–1148

    PubMed  CAS  Google Scholar 

  48. Gower WR (1993) Mechanism of glucocorticoid action. J Fla Med Assoc 80: 697–700

    PubMed  Google Scholar 

  49. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, Rustin M, Downes N (1994) Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 130: 483–487

    Article  PubMed  CAS  Google Scholar 

  50. Grossman RM, Thivolet J, Claudy A, et al. (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 31: 68–74

    PubMed  CAS  Google Scholar 

  51. Guenther L, Van de Kerkhof PC, Snellman E, et al. (2002) Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 147: 316–323

    Article  PubMed  CAS  Google Scholar 

  52. Guzzo C, Lazarus G, Goffe BS, Katz HI, Lowe NJ, Pincus SH (1996) Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. J Am Acad Dermatol 34: 429–433

    Article  PubMed  CAS  Google Scholar 

  53. Hanke CW, Steck WD, Roegnick HH Jr (1979) Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol 115: 1074–1077

    Article  PubMed  CAS  Google Scholar 

  54. Hardman KA, Heath DA, Nelson HM (1993) Hypercalcaemia associated with calcipotriol (Dovonex) treatment. BMJ 306: 896

    PubMed  CAS  Google Scholar 

  55. Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M (1999) Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 41: 927–930

    Article  PubMed  CAS  Google Scholar 

  56. Hecker D, Worsley J, Yueh G, Lebwohl M (2000) In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol 42: 1008–1011

    Article  PubMed  CAS  Google Scholar 

  57. Hein R, Krieg T (1988) Effects of corticosteroids on human fibroblasts in vitro. In: Christophers E, Schopf E, Kligman AM, et al. (eds) Topical corticosteroid therapy: a novel approach to safer drugs. Raven Press, New York, pp 57–65

    Google Scholar 

  58. Highton A, Quell J (1995) Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 32: 67–72

    Article  PubMed  CAS  Google Scholar 

  59. Ingram JT (1953) The approach to psoriasis. Br Med J 2: 591

    PubMed  CAS  Google Scholar 

  60. Jorizzo JL, Magee K, Stewart DM, et al. (1997) Clobetasol propionate emollient 0.05%: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis. Cutis 60: 55–60

    PubMed  CAS  ISI  Google Scholar 

  61. Kaidbey KH, Kligman AM (1977) Clinical and histological study of coal tar phototoxicity in humans. Arch Dermatol 113: 592–595

    Article  PubMed  CAS  Google Scholar 

  62. Kanzler MH, Gorsulowsky DC (1993) Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. Br J Dermatol 129: 310–314

    Article  PubMed  CAS  Google Scholar 

  63. Katoh N, Kishimoto S (2003) Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis. Eur J Dermatol 13: 382–384

    PubMed  CAS  Google Scholar 

  64. Katz HI, Hien NT, Pauer SE, et al. (1987) Superpotent topical steroid treatment of psoriasis vulgaris — clinical efficacy and adrenal function. J Am Acad Dermatol 16: 804–811

    Article  PubMed  CAS  Google Scholar 

  65. Katz HI, Gross E, Buxman M, Prawer SE, Schwartzel EH, Gibson JR (1991) A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol 25: 1175–1188

    PubMed  CAS  Google Scholar 

  66. Katz HI, Prawer SE, Medansky RS, Kreuger GG, Mooney JJ, Jones ML, Samson CR (1991) Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind, multi-center trial of augmented betamethasone dipropionate ointment in a pulse dose regimen. Dermatologica 183: 269–274

    PubMed  CAS  ISI  Google Scholar 

  67. Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R, Cornell R, Pariser DM, Pariser RJ, Weng W, et al. (1995) Efficacy and safety of twice-daily augmented betamethasone lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 17: 390–401

    Article  PubMed  CAS  Google Scholar 

  68. Kaufmann R, Bibby AJ, Bissonnette R, et al. (2002) A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205: 389–393

    Article  PubMed  CAS  ISI  Google Scholar 

  69. Kienbaum S, Lehmann P, Ruzicka T (1996) Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 135: 647–650

    Article  PubMed  CAS  Google Scholar 

  70. Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. (1994) Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 131: 678–683

    Article  PubMed  CAS  Google Scholar 

  71. Klem EB (1978) Effects of antipsoriasis drugs and metabolic inhibitors on the growth of epidermal cells in culture. J Invest Dermatol 70: 27–32

    Article  PubMed  CAS  Google Scholar 

  72. Kneczke M, Rahm C, Landersjo L (1990) The influence of salicylic acid on the in vitro release of anthralin from an o/w cream. Acta Pharm Nordica 2: 313–318

    CAS  Google Scholar 

  73. Koo J (1995) Diluting Dovonex. Psoriasis Forum 1: 6

    Google Scholar 

  74. Koo J (1997) Calcipotriol/calcipotriene (Dovonex/Daivonex) in combination with phototherapy: a review. J Am Acad Dermatol 37: S59–61

    PubMed  CAS  Google Scholar 

  75. Koo J, Cuffie CA, Tanner DJ, et al. (1998) Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 20: 283–291

    Article  PubMed  CAS  Google Scholar 

  76. Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR (2000) Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 43: 821–828

    Article  PubMed  CAS  Google Scholar 

  77. Koo JY, Martin D (2001) Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 40: 210–212

    Article  PubMed  CAS  Google Scholar 

  78. Kragbelle K (1988) MC903, a non-calciotropic vitamin D3 analogue stimulates differentiation and inhibits proliferation of cultured human keratinocytes. J Invest Dermatol 91: 383

    Google Scholar 

  79. Kragbelle K (1989) Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh) 151: 7–10; 47–52

    Google Scholar 

  80. Kragballe K (1989) Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 125: 1647–1652

    Article  PubMed  CAS  Google Scholar 

  81. Kragballe K, Gjertsen BT, De Hoop D, et al. (1991) Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 26; 337(8735): 193–196

    Article  CAS  Google Scholar 

  82. Kragbelle K (1996) Vitamin D3 analogues. Dermatol Clin 13: 835–838

    Google Scholar 

  83. Krayenbuhl BH, Elsner P (1999) Allergic and irritant contact dermatitis to calcipotriol. Am J Contact Dermat 10: 78–80

    Article  PubMed  CAS  Google Scholar 

  84. Krochmal L, Wang JC, Patel B, Rodgers J (1989) Topical corticosteroid compounding: effects on physiochemical stability and skin penetration rate. J Am Acad Dermatol 21: 979–984

    PubMed  CAS  Google Scholar 

  85. Krueger GG, Drake LA, Elias PM, et al. (1998) The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 134: 57–60

    Article  PubMed  CAS  Google Scholar 

  86. Kubo T, Kojima A, Yamazoe S, Ueshima K, Yamamoto T, Hirasawa Y (2001) Osteonecrosis of the femoral head that developed after long-term topical steroid application. J Orthop Sci 6: 92–94

    Article  PubMed  CAS  Google Scholar 

  87. Larko O, Swanbeck G, Svartholm H (1984) The effect on psoriasis of clobetasol propionate used alone or in combination with UVB. Acta Derm Venereol 64: 151–154

    PubMed  CAS  Google Scholar 

  88. Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, Moore J (1996) A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 35: 268–269

    Article  PubMed  CAS  Google Scholar 

  89. Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B (1997) Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol 37: 93–95

    Article  PubMed  CAS  Google Scholar 

  90. Lebwohl M, Ast E, Callen JP, et al. (1998) Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 38: 705–711

    Article  PubMed  CAS  Google Scholar 

  91. Lebwohl MG, Breneman DL, Goffe BS, et al. (1998) Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 39: 590–596

    Article  PubMed  CAS  Google Scholar 

  92. Lebwohl M, Yoles A, Lombardi K, Lou W (1998) Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 39: 447–450

    Article  PubMed  CAS  Google Scholar 

  93. Lebwohl M (1999) The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 38: 16–24

    Article  PubMed  CAS  Google Scholar 

  94. Lebwohl M (2000) Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 43: S43–46

    Article  PubMed  CAS  Google Scholar 

  95. Lebwohl MG, Tan MH, Meador SL, Singer G (2001) Limited application of fluticasone propionate ointment 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 44: 77–82

    Article  PubMed  CAS  Google Scholar 

  96. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR (2002) A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 41: 269–274

    Article  PubMed  CAS  Google Scholar 

  97. Lesnik RH, Mezick JA, Capetola R, Kligman LH (1989) Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. J Am Acad Dermatol 21: 186–190

    Article  PubMed  CAS  Google Scholar 

  98. Levin C, Maibach HI (2002) Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 3: 141–147

    Article  PubMed  Google Scholar 

  99. Leyden JJ, Thew M, Kligman AM (1974) Steroid rosacea. Arch Dermatol 110: 619–622

    Article  PubMed  CAS  Google Scholar 

  100. Marsico RE, Dijkstra JW (1996) UVB blocking effect of calcipotriene ointment 0.005%. J Am Acad Dermatol 34: 539–540

    Article  PubMed  CAS  Google Scholar 

  101. Marsland AM, Griffiths CE (2002) The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 12: 618–622

    PubMed  CAS  Google Scholar 

  102. Mason J, Mason AR, Cork MJ (2002) Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 146: 351–364

    Article  PubMed  CAS  Google Scholar 

  103. McKenzie AW, Stoughton RB (1962) Methods for comparing percutaneous absorption of steroids. Arch Dermatol 86: 608–610

    Google Scholar 

  104. Medansky RS, Cuffie CA, Tanner DJ (1997) Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Clin Ther 19: 701–709

    Article  PubMed  CAS  Google Scholar 

  105. Melian EB, Spencer CM, Jarvis B (2001) Clobetasol propionate foam, 0.05%. Am J Dermatol 2: 89–92

    Article  CAS  Google Scholar 

  106. Menter A (2000) Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 43: S31–35

    Article  PubMed  CAS  Google Scholar 

  107. Meola T Jr, Soter NA, Lim HW (1991) Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature. Arch Dermatol 127: 1708–1713

    Article  PubMed  Google Scholar 

  108. Milde P, Hauser U, Simon T, Mall G, Ernst V, Haussler MR, Frosch P, Rauterberg EW (1991) Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 97: 230–239

    Article  PubMed  CAS  Google Scholar 

  109. Miller JA, Munro DD (1980) Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 19: 119–134

    Article  PubMed  CAS  ISI  Google Scholar 

  110. Molin L, Cutler TP, Helander I, Nyfors B, Downes N (1997) Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 136: 89–93

    Article  PubMed  CAS  Google Scholar 

  111. Morison WL, Parrish JA, Fitzpatrick TB (1978) Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis. Br J Dermatol 98: 125–132

    Article  PubMed  CAS  Google Scholar 

  112. Nathan AW, Rose GL (1979) Fatal iatrogenic Cushing’s syndrome. Lancet 1: 207

    Article  PubMed  CAS  ISI  Google Scholar 

  113. Nielson NV, Sorensen PN (1978) Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol 114: 953–954

    Article  Google Scholar 

  114. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, Lasser AE, Lebwohl M, Leibsohn E, Medansky RS, et al. (1991) A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 24: 443–447

    Article  PubMed  CAS  Google Scholar 

  115. Patel B, Siskin S, Krazmien R, Lebwohl M (1998) Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 38: 1010–1011

    Article  PubMed  CAS  Google Scholar 

  116. Plewig G, Kligman AM (1973) Induction of acne by topical steroids. Arch Dermatol Forsch 247: 29–52

    Article  PubMed  CAS  Google Scholar 

  117. Ramsay B, Lawrence CM, Bruce JM, Shuster S (1990) The effect of triethanolamine on anthralininduced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 23: 73–76

    PubMed  CAS  Google Scholar 

  118. Ramsay CA, Berth-Jones J, Brundin G, et al. (1994) Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 189: 260–264

    PubMed  CAS  ISI  Google Scholar 

  119. Ramsay C (1997) Management of psoriasis with calcipotriol used as monotherapy. J Am Acad Dermatol 37: S53–S54

    PubMed  CAS  Google Scholar 

  120. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M (2000) Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 200: 17–24

    Article  PubMed  CAS  ISI  Google Scholar 

  121. Rigby WFC (1988) The immunobiology of vitamin D. Immunol Today 9: 54–58

    Article  PubMed  CAS  Google Scholar 

  122. Runne U, Kunze J (1982) Short duration (“minutes”) therapy with dithranol for psoriasis: A new outpatient regimen. Br J Dermatol 106: 135–139

    Article  PubMed  CAS  Google Scholar 

  123. Silverman A, Menter A (1995) Tars and anthralins. Dermatol Clin 13: 817–833

    PubMed  CAS  Google Scholar 

  124. Singh S, Reddy DC, Pandey SS (2000) Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 43: 61–65

    Article  PubMed  CAS  Google Scholar 

  125. Sneddon I (1969) Adverse effect of topical fluorinated corticosteroids in rosacea. Br Med J 1: 671–673

    PubMed  CAS  Google Scholar 

  126. Sneddon IB (1980) Perioral dermatitis. Br J Dermatol 102: 239–240

    Article  PubMed  CAS  Google Scholar 

  127. Speight EL, Farr PM (1994) Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 130: 79–82

    Article  PubMed  CAS  Google Scholar 

  128. Stegman SJ (1974) Pustular dermatosis on withdrawal of topically applied steroid. Arch Dermatol 109: 100

    Article  PubMed  CAS  Google Scholar 

  129. Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U (2001) Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 5: 303–307

    Article  PubMed  CAS  Google Scholar 

  130. Stevanovic DV (1972) Corticosteroid-induced atrophy of the skin with telangiectasia. A clinical and experimental study. Br J Dermatol 87: 548–556

    Article  PubMed  CAS  Google Scholar 

  131. Svartholm H, Larsson L, Fredereiksen B (1982) Intermittent topical treatment of psoriasis with clobetasol propionate (Dermovate). Curr Med Res Opin 8: 154–157

    PubMed  CAS  Google Scholar 

  132. Tanenbaum L, Parrish JA, Pathak MA, Anderson RR, Fitzpatrick TB (1975) Tar phototoxicity and phototherapy for psoriasis. Arch Dermatol 111: 467–470

    Article  PubMed  CAS  Google Scholar 

  133. Tang-Liu DD, Matsumoto RM, Usansky JI (1999) Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 37: 273–287

    Article  PubMed  CAS  Google Scholar 

  134. Thaci D, Daiber W, Boehncke WH, Kaufmann R (2001) Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 203: 153–156

    Article  PubMed  CAS  ISI  Google Scholar 

  135. Tham SN, Lun KC, Cheong WK (1994) A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 131: 673–677

    Article  PubMed  CAS  Google Scholar 

  136. Thune P, Brolund L (1992) Short-and long-contact therapy using a new dithranol formulation in individually adjusted doses in the management of psoriasis. Acta Derm Venereol Suppl (Stockh) 172: 28–29

    CAS  Google Scholar 

  137. Turpeinen M, Salo OP, Leisti S (1986) Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 115: 475–484

    Article  PubMed  CAS  Google Scholar 

  138. Tzaneva S, Honigsmann H, Tanew A, Seeber A (2002) A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 147: 748–753

    Article  PubMed  CAS  Google Scholar 

  139. Tzaneva S, Honigsmann H, Tanew A (2003) Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol 149: 350–353

    Article  PubMed  CAS  Google Scholar 

  140. Ultravate [package insert] (2000) Bristol-Myers-Squibb Dermatology, Princeton, NJ

    Google Scholar 

  141. van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. (1998) The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 138: 84–89

    Article  PubMed  Google Scholar 

  142. Vicker CFH (1963) Existence of a reservoir in the stratum corneum. Arch Dermatol 88: 20–23

    Google Scholar 

  143. Wang JC, Krazmien RJ, Dahlheim CE, et al. (1986) Anthralin stain removal. J Am Acad Dermatol 15: 951–955

    Article  PubMed  CAS  Google Scholar 

  144. Weinstein GD, Krueger GG, Lowe NJ, et al. (1997) Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 37: 85–92

    Article  PubMed  CAS  Google Scholar 

  145. Weinstein GD, Koo JY, Krueger GG, et al. (2003) Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 48: 760–767

    Article  PubMed  Google Scholar 

  146. Woo WK, McKenna KE (2003) Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol 149: 146–150

    Article  PubMed  CAS  Google Scholar 

  147. Yohn JJ, Weston WL (1990) Topical glucocorticosteroids. Curr Probl Dermatol 2: 38–63

    Google Scholar 

  148. Zonneveld IM, Rubins A, Jablonska S, et al. (1998) Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134: 1101–1102

    Article  PubMed  CAS  Google Scholar 

References

  1. Asawanonda P, Anderson RR, Chang Y, Taylor CR (2000) 308 nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol 136: 619–624

    Article  PubMed  CAS  Google Scholar 

  2. Carlin CS, Callis KP, Krueger GG (2003) Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 139: 436–442

    Article  PubMed  CAS  Google Scholar 

  3. Coven TR, Walters IB, Cardinale I, Kruger JP (1999) PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 15(1): 22–27

    PubMed  CAS  Google Scholar 

  4. Dawes RS, Wainright NJ, Cameron H, Ferguson J (1998) Narrowband ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 138: 833–839

    Article  Google Scholar 

  5. Duthie MS, Kimber I, Norval M (1999) The effects of ultraviolet radiation on the human immune system. Br J Dermatol 140: 995–1009

    Article  PubMed  CAS  Google Scholar 

  6. Feldman SR, et al. (2002) Efficacy of the 308 nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 46: 732–737

    Article  Google Scholar 

  7. Fisher T (1976) UV-light treatment of psoriasis. Acta Derm Venereol 56: 473–479

    Google Scholar 

  8. Fleischer AB Jr, Clark AR, Rapp SR, Reboussin DM, Feldman SR (1997) Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol 109: 170–174

    Article  PubMed  Google Scholar 

  9. Garssen J, van Loveren H (2001) Effects of ultraviolet exposure on the immune system. Crit Rev Immunol 21: 359–397

    PubMed  CAS  Google Scholar 

  10. Gibbs ND, McCloone RP, Simics E (1997) An action spectrum for urocanic acid in human skin in vivo. Photochem Photobiol 65: 103S–104S

    Article  Google Scholar 

  11. Green C, Ferguson J, Lakshmipathi T, Johnson BE (1988) 311 nm UVB phototherapy — an effective treatment for psoriasis. Br J Dermatol 119: 691–696

    Article  PubMed  CAS  Google Scholar 

  12. Guenther LC (2003) Optimizing treatment with topical tazarotene. Am J Clin Dermatol 4: 197–202

    Article  PubMed  Google Scholar 

  13. Hofer A, Fink-Puches R, Kerl H, Wolf P (1998) Comparison of phototherapy with near vs. far erythemogenic doses of narrow band ultraviolet B in patients with psoriasis. Br J Dermatol 138: 96–100

    Article  PubMed  CAS  Google Scholar 

  14. Honigsmann H (2001) Phototherapy for psoriasis. Clin Exp Dermatol 26: 343–350

    Article  PubMed  CAS  Google Scholar 

  15. Iest J, Boer J (1989) Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 120: 665–670

    Article  PubMed  CAS  Google Scholar 

  16. Kammeyer A, Teunissen MB, Pavel S, de Rie MA, Bos JD (1995) Photoisomerization spectrum of urocanic acid in human skin and in vitro: effects of simulated solar and artificial ultraviolet radiation. Br J Dermatol 132: 884–891

    PubMed  CAS  Google Scholar 

  17. Koo J, Behnam SE, Behnam SM (2003) The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. Expert Opin Pharmacother 4: 2347–2354

    Article  PubMed  CAS  Google Scholar 

  18. Kragballe K (2002) Vitamin D and UVB radiation therapy. Cutis 70: 9–12

    PubMed  ISI  Google Scholar 

  19. Krutmann J (1998) Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)-therapy. J Photochem Photobiol B 44: 159–164

    Article  PubMed  CAS  Google Scholar 

  20. Larko O (1989) Treatment of psoriasis with a new UVB-lamp. Acta Derm Venereol 69: 357–359

    PubMed  CAS  Google Scholar 

  21. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, et al. (2001) Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 45: 544–553

    Article  PubMed  CAS  Google Scholar 

  22. Lebwohl M, Quijije J, Gilliard J, Rollin T, Watts O (2003) Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol 121: 594–595

    Article  PubMed  CAS  Google Scholar 

  23. Lowe N, Prystowsky JH, Gourget T, Edelstein J, Nychay S, Armstrong R (1991) Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 24: 591–594

    Article  PubMed  CAS  Google Scholar 

  24. Lowe, Iest, Tanew, Lebwohl (1999)

    Google Scholar 

  25. Marcil I, Stern RS (2001) Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: nested cohort crossover study. Lancet 358: 1042–1045

    Article  PubMed  CAS  ISI  Google Scholar 

  26. Mascaro JM (2002) Vitamin D and psoralens plus UVA radiation. Cutis 70: 13–15

    PubMed  ISI  Google Scholar 

  27. Morison WL, Momtax K, Parrish JA, Fitzpatrick TB (1982) Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 6: 46–51

    Article  PubMed  CAS  Google Scholar 

  28. Ozawa M, Ferenczi K, Kikuchi T, et al. (1999) 312 nm UV induces apoptosis of T cells. J Exp Med 189: 711–718

    Article  PubMed  CAS  Google Scholar 

  29. Parrish JA, Jaenicke KF (1981) Action spectrum for phototherapy of psoriasis. J Invest Dermatol 76: 359–362

    Article  PubMed  CAS  Google Scholar 

  30. Paul BS, Momtax K, Stern RS, Arndt KA, Parrish JA (1982) Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 7: 758–762

    Article  PubMed  CAS  Google Scholar 

  31. Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL (1982) Cutaneous squamous cell carcinoma in patients treated with PUVA. N Engl J Med 310: 1156–1161

    Google Scholar 

  32. Stern RS, Laird N (1994) The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 77: 2759–2764

    Article  Google Scholar 

  33. Tanew A, Guggenbilcher A, Honigsmann H, Geiger JM, Fritsch P (1999) Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double blind comparison study. J Am Acad Dermatol 41: S25–28

    Article  Google Scholar 

  34. Trehan M, Taylor CR (2002) High dose 308 nm laser for the treatment of psoriasis. J Am Acad Dermatol 46: 732–737

    Article  PubMed  Google Scholar 

  35. Van Weelden H, De La Faille HB, Young E, Van der Leun IC (1988) A new development in UVB phototherapy of psoriasis. Br J Dermatol 119: 11–19

    Article  PubMed  Google Scholar 

  36. Van Weelden H, Baart de la Faille H, Young E, Van der Leun JC (1990) Comparison of narrow-band UVB phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol 70: 212–215

    PubMed  Google Scholar 

  37. Walters IB, Burack LH, Coven TR, Gilleaudeu P, Krueger JG (1999) Suberythemogenic narrowband UVB is markedly more effective than conventional UVB treatment of psoriasis vulgaris. J Am Acad Dermatol 40: 893–900

    Article  PubMed  CAS  Google Scholar 

  38. Zanolli M (2003) The modern paradigm of phototherapy. Clin Dermatol 21: 398–406

    Article  PubMed  Google Scholar 

References

  1. [No author] Soriatane [package insert] (1997) Roche Laboratories, Nutley, NJ

    Google Scholar 

  2. [No author] Two new retinoids for psoriasis (1997) Medical Letter on Drugs & Therapeutics 39(1013): 105–106

    Google Scholar 

  3. Anstey A, Hawk JLM (1997) Isotretinoin-PUVA in women with psoiasis. Br J Dermatol 136: 798–799

    Article  PubMed  CAS  Google Scholar 

  4. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE (2000) Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol 136: 1536–1543

    Article  PubMed  CAS  Google Scholar 

  5. Berbis P, Bun H, Geiger JM, et al. (1988) Acitretin (RO10-1670) and oral contraceptives: interaction study. Arch Dermatol Res 280: 388–389

    Article  PubMed  CAS  Google Scholar 

  6. Berbis P, Geiger JM, Vaisse C, Rognin C, Privat Y (1989) Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 178: 88–92

    PubMed  CAS  ISI  Google Scholar 

  7. Bernstein RE (1984) Liver and hypervitaminosis. N Engl J Med 311: 604

    Article  PubMed  CAS  Google Scholar 

  8. Berth-Jones J, Shuttleworth D, Hutchinson PE (1990) A study of etretinate alopecia. Br J Dermatol 122: 751–755

    Article  PubMed  CAS  Google Scholar 

  9. Brindley C (1989) An overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, Etretin). Dermatologica 178: 79–87

    PubMed  CAS  ISI  Google Scholar 

  10. Carlin CS, Callis KP, Krueger GG (2003) Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 139: 436–442

    Article  PubMed  CAS  Google Scholar 

  11. Cesario RM, Klausing K, Razzaghi H, et al. (2001) The rexinoid LG100754 is a novel RXR: PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol 15: 1360–1369

    Article  PubMed  CAS  Google Scholar 

  12. Chandraratna RA (1998) Rational design of receptor-selective retinoids. J Am Acad Dermatol 39: S124–S128

    Article  PubMed  CAS  Google Scholar 

  13. Chandraratna RA (1996) Tazarotene — first of a new generation of receptor-selective retinoids. Br J Dermatol 135: S18–S25

    Article  Google Scholar 

  14. Cunningham WJ (1991) Side effect profile of retinoids. In: Roenigk HH Jr, Maibach HI (eds) Psoriasis, 2nd edn. Marcel Dekker, New York, pp 769–774

    Google Scholar 

  15. Dicken CH (1994) Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol 31: 997–999

    PubMed  CAS  Google Scholar 

  16. DiGiovanna JJ (2001) Systemic retinoid therapy. Dermatol Clin 19: 161–167

    PubMed  CAS  Google Scholar 

  17. DiGiovanna JJ, Helfgott RK, Gerber LH, Peck GL (1986) Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 315: 1177–1182

    Article  PubMed  CAS  Google Scholar 

  18. DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC (1995) Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 131: 1263–1267

    Article  PubMed  CAS  Google Scholar 

  19. Elder JT, Fisher GJ, Zhang Q-Y, et al. (1991) Retinoic acid receptor gene expression in human skin. J Invest Dermatol 96: 425–433

    Article  PubMed  CAS  Google Scholar 

  20. Frati C, Bevilacqua L, Apostolico V (1994) Association of etretinate and fish oil in psoriasis therapy. Inhibition of hypertriglyceridemia resulting from retinoid therapy after fish oil supplementation. Acta Derma Venereol 186: S151–S153

    Google Scholar 

  21. Geiger JM, Czarnetzki BM (1988) Acitretin (RO10-1670, Etretin): overall evaluation of clinical studies. Dermatologica 176: 182–190

    Article  PubMed  CAS  ISI  Google Scholar 

  22. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ (1988) Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 18: S655–S662

    Article  Google Scholar 

  23. Gollnick H, Bauer R, Brindley C, et al. (1988) Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 19: 458–468

    Article  PubMed  CAS  Google Scholar 

  24. Goodman DS (1984) Vitamin A and retinoids in health and disease. N Engl J Med 310: 1023–1031

    PubMed  CAS  Google Scholar 

  25. Gronhoj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F (2000) Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 143: 1164–1169

    Article  PubMed  CAS  Google Scholar 

  26. Iest J, Boer J (1989) Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 120: 665–670

    Article  PubMed  CAS  Google Scholar 

  27. Jones PH, Burnett RD, Fainaru I, et al. (2003) A phase 1 study of tazarotene in adults with advanced cancer. Br J Cancer 89: 808–815

    Article  PubMed  CAS  Google Scholar 

  28. Kane EK (1971) Arctic explorations in 1853, 1854, 1855. Arno Press and The New York Times, New York, vol 1, pp 392–393

    Google Scholar 

  29. Kano Y, Fukuda M, Shiohara T, Nagashima M (1994) Cholestatic hepatitis occurring shortly after etretinate therapy. J Am Acad Dermatol 31: 133–134

    Article  PubMed  CAS  Google Scholar 

  30. Kaplan RP, Russell DH, Lowe NJ (1983) Etretinate therapy for psoriasis: Clinical responses, remission times, epidermal DNA and polyamine responses. J Am Acad Dermatol 8: 95–102

    Article  PubMed  CAS  Google Scholar 

  31. Katz HI, Waalen J, Leach EE (1999) Acitretin in psoriasis: An overview of adverse effects. J Am Acad Dermatol 41: S7–S12

    Article  PubMed  CAS  Google Scholar 

  32. Khouri MR, Saul SH, Dlugosz AA, Soloway RD (1987) Hepatocanalicular injury associated with vitamin A derivative etretinate: An idiosyncratic hypersensitivity reaction. Dig Dis Sci 32: 1207–1211

    Article  PubMed  CAS  Google Scholar 

  33. Kreiss C, Amin S, Nalesnik MA, Chopra K, Shakil AO (2002) Severe cholestatic hepatitis in a patient taking acitretin. Am J Gastroenterol 97: 775–777

    Article  PubMed  Google Scholar 

  34. Lammer EJ, Chen CT, Hoar RM, et al. (1985) Retinoic acid embryopathy. N Engl J Med 313: 837–841

    Article  PubMed  CAS  Google Scholar 

  35. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F (1993) Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 100: 623–627

    Article  PubMed  CAS  Google Scholar 

  36. Lauharanta J, Juvakoski T, Lassus A (1981) A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol 104: 325–332

    Article  PubMed  CAS  Google Scholar 

  37. Lebwohl M, Ali S (2001) Treatment of psoriasis, part 2. Systemic therapies. J Am Acad Dermatol 45: 649–661

    Article  PubMed  CAS  Google Scholar 

  38. Lee AG (1995) Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 55: 165–168

    PubMed  CAS  ISI  Google Scholar 

  39. Leyden JJ (1998) The role of isotretinoin in the treatment of acne: personal observations. J Am Acad Dermatol 39: S45–49

    Article  PubMed  CAS  Google Scholar 

  40. Ling MR (1999) Acitretin: Optimal dosing strategies. J Am Acad Dermatol 41: S13–S17

    Article  PubMed  CAS  Google Scholar 

  41. Lowe MN, Plosker GL (2000) Bexarotene. Am J Clin Dermatol 1: 245–250

    Article  PubMed  CAS  Google Scholar 

  42. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R (1991) Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 24: 591–594

    Article  PubMed  CAS  Google Scholar 

  43. Mantel-Teeuwise AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A (2001) Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety 34: 443–456

    Article  Google Scholar 

  44. Marsden JR (1987) Effect of dietary fish oil on hyperlipidaemia due to isotretinoin and etretinate. Hum Toxicol 6: 219–222

    Article  PubMed  CAS  Google Scholar 

  45. McKenna DB, Murphy GM (1999) Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 140: 656–660

    Article  PubMed  CAS  Google Scholar 

  46. McNamara PJ, Jewell RC, Jensen BK, Brindley CJ (1988) Food increases the bioavailability of acitretin. J Clin Pharmacol 28: 1051–1055

    PubMed  CAS  Google Scholar 

  47. Milstone LM, McGuire J, Ablow RC (1982) Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 7: 663–666

    PubMed  CAS  Google Scholar 

  48. Mork N, Kolbenstvedt A, Austad J (1996) Skeletal side-effects of 5 years acitretin treatment. Br J Dermatol 134: 1156–1157

    Article  PubMed  CAS  Google Scholar 

  49. Moy RL, Kingston TP, Lowe NJ (1985) Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 121: 1297–1301

    Article  PubMed  CAS  Google Scholar 

  50. Muchenberger S, Schopf E, Simon JC (1997) The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol 137: 587–589

    Article  PubMed  CAS  Google Scholar 

  51. Nguyen EQH, Wolverton SE (2002) Systemic Retinoids. In: Wolverton SE (ed) Comprehensive dermatologic drug therapy. WB Saunders, Philadelphia, pp 269–310

    Google Scholar 

  52. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC (1997) Current use and future potential role of retinoids in dermatology. Drugs 53: 358–388

    Article  PubMed  CAS  ISI  Google Scholar 

  53. Peck GL, DiGiovanna JJ (1999) The retinoids. In: Freedberg IM, Eisen AZ, Wolff K, et al. (eds) Dermatology in general medicine. McGraw-Hill, New York, pp 2810–2820

    Google Scholar 

  54. Peck GL, Yoder FW (1976) Treatment of lamellar ichthyosis and other keratinizing dermatoses with a synthetic retinoid. Lancet 2: 1172–1174

    Article  PubMed  CAS  ISI  Google Scholar 

  55. Prendiville J, Bingham EA, Burrows D (1986) Premature epiphyseal closure — a complication of etretinate therapy in children. J Am Acad Dermatol 15: 1259–1262

    PubMed  CAS  Google Scholar 

  56. Raica N Jr, Scot J, Lowry L, et al. (1972) Vitamin A concentration in human tissues collected in five areas in the United States. Am J Clin Nutr 25: 291–296

    PubMed  Google Scholar 

  57. Roenigk HH, Callen JP, Guzoo CA, et al. (1999) Effects of acitretin on the liver. J Am Acad Dermatol 41: 584–588

    PubMed  Google Scholar 

  58. Rosa FW, Wilk AL, Kelsey FO (1986) Teratogen update: Vitamin A congeners. Teratology 33: 355–364

    Article  PubMed  CAS  ISI  Google Scholar 

  59. Ruzicka T, Sommerburg C, Braun-Falco O, et al. (1990) Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 126: 482–486

    Article  PubMed  CAS  Google Scholar 

  60. Saurat JH (1999) Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41: S2–S6

    Article  PubMed  CAS  Google Scholar 

  61. Saurat JH, Geiger JM, Amblard P, et al. (1988) Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA, and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 177: 218–224

    PubMed  CAS  ISI  Google Scholar 

  62. Schroder K, Zaun H, Holzmann H, et al. (1989) Pustulosis palmo-plantaris. Clinical and histological changes during etretin (acitretin). Acta Derm Venereol 146: S111–S116

    Google Scholar 

  63. Shukenboom M, Middelbeek A, De Jong-Van den Berg L, et al. (1995) Vulvo-vaginal candidiasis associated with acitretin. J Clin Epidemiol 48: 991–997

    Article  Google Scholar 

  64. Silverman AK, Ellis CN, Voorhees JJ (1987) Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J Am Acad Dermatol 16: 1027–1039

    Article  PubMed  CAS  Google Scholar 

  65. Smith J, de Jong E, van Hooijdonk C, et al. (2000) A multicentre phase ii clinical and immunohisto-chemical trial of systemic bexarotene (Targretin) in psoriasis. J Invest Derm 114: 776

    Google Scholar 

  66. Streit V, Wiedow O, Christophers E (1996) Treatment of psoriasis with polyethylene sheet bath PUVA. J Am Acad Dermatol 35: 208–210

    Article  PubMed  CAS  Google Scholar 

  67. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P (1991) Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 25: 682–684

    PubMed  CAS  Google Scholar 

  68. Turner RJ, Farr PM, Walshaw D (1998) Many patients with psoriasis use sunbeds. Br Med J 317: 412

    CAS  Google Scholar 

  69. Vahlquist A, Rollman O (1987) Clinical pharmacology of 3 generations of retinoids. Dermatologica 175: S20–S27

    Google Scholar 

  70. van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. (1998) The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 138: 84–89

    Article  PubMed  Google Scholar 

  71. van Dietzhujsen TJM, van Haelst UJGM, van Dooren-Greebe RJ, et al. (1990) Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol 11: 185–188

    Article  Google Scholar 

  72. van Dooren-Greebe RJ, Lemmens JA, De Boo T, Hangx NM, Kuijpers AL, van de Kerkhof PC (1996) Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 134: 71–76

    Article  PubMed  Google Scholar 

  73. Wiegand UW, Chou RC (1998) Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 39: S25–S33

    Article  PubMed  CAS  Google Scholar 

  74. Wolbach SB, Howe PR (1925) Tissue changes following deprivation of fat soluble A vitamin. J Exp Med 43: 753–757

    Article  Google Scholar 

  75. Wolverton SE (1991) Retinoids. In: Wolverton SE, Wilkin JK (eds) Systemic drugs for skin diseases. WB Saunders, Philadelphia, pp 187–218

    Google Scholar 

  76. Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ (2003) Systemic retinoids. In: Weinstein GD, Gottlieb AB (eds) Therapy of moderate-to-severe psoriasis, 2nd edn. Marcel Dekker, New York, pp 137–150

    Google Scholar 

  77. http://www.allergan.com/site/investors/pr details. asp?id =104739.Mar 24, 2003, Business Wire Magazine

    Google Scholar 

References

  1. Berth-Jones J, Voorhees JJ (1996) Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol 135: 775–777

    Article  PubMed  CAS  Google Scholar 

  2. Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM (1995) Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 133: 774–778

    Article  PubMed  CAS  Google Scholar 

  3. Boffa MJ, Smith A, Chalmers RJ, Mitchell DM, Rowan B, Warnes TW, Shomaf M, Haboubi NY (1996) Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 135: 538–544

    Article  PubMed  CAS  Google Scholar 

  4. Callaway JL, McAfee WC, Finlayson GR (1966) Management of psoriasis using methotrexate orally in a single weekly dose. South Med J 59: 424–426

    PubMed  CAS  Google Scholar 

  5. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger CG (2003) A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint. J Invest Dermatol 121(1): 0393 (Abstract)

    Google Scholar 

  6. Casserly CM, Stange KC, Chren MM (1993) Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. J Am Acad Dermatol 29: 477–480

    PubMed  CAS  Google Scholar 

  7. Cather JC, Abramovits W, Menter A (2001) Cyclosporine and tacrolimus in dermatology. Dermatol Clin 19: 119–137, ix

    Article  PubMed  CAS  Google Scholar 

  8. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, Saihan EM, Chalmers RJ, Barker JN, Allen BR, Griffiths CE (1999) Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 141: 279–282

    Article  PubMed  CAS  Google Scholar 

  9. Constantin A, Loubet-Lescoulie P, Lambert N, Yassine-Diab B, Abbal M, Mazieres B, de Preval C, Cantagrel A (1998) Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 41: 48–57

    Article  PubMed  CAS  Google Scholar 

  10. Cronstein BN (1997) The mechanism of action of methotrexate. Rheum Dis Clin North Am 23: 739–755

    Article  PubMed  CAS  Google Scholar 

  11. Cronstein BN, Eberle MA, Gruber HE, Levin RI (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 88: 2441–2445

    Article  PubMed  CAS  Google Scholar 

  12. Dayan M, Segal R, Mozes E (1997) Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosus. J Rheumatol 24: 1075–1082

    PubMed  CAS  Google Scholar 

  13. de Jong EM, Mork NJ, Seijger MM, De La BM, Lauharanta J, Jansen CT, Guilhou JJ, Guillot B, Ostrojic A, Souteyrand P, Vaillant L, Barnes L, Rogers S, Klaber MR, van de Kerkhof PC (2003) The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 148: 318–325

    Article  PubMed  Google Scholar 

  14. Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, van de Kerkhof PC (1994) Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 130: 204–210

    Article  PubMed  Google Scholar 

  15. Duhra P (1993) Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 28: 466–469

    PubMed  CAS  Google Scholar 

  16. Dupuy P, Bagot M, Michel L, Descourt B, Dubertret L (1991) Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol 96: 408–413

    Article  PubMed  CAS  Google Scholar 

  17. Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ (1995) Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 131: 791–795

    Article  PubMed  CAS  Google Scholar 

  18. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG (1991) Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324: 277–284

    Article  PubMed  CAS  Google Scholar 

  19. Furue M, Katz SI (1988) The effect of cyclosporine on epidermal cells. I. Cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro. J Immunol 140: 4139–4143

    PubMed  CAS  Google Scholar 

  20. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP (1998) Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102: 322–328

    Article  PubMed  CAS  Google Scholar 

  21. Georgouras KE, Zagarella SS, Cains GD, Brown PJ (1997) Systemic treatment of severe psoriasis. Australas J Dermatol 38: 171–180

    Article  PubMed  CAS  Google Scholar 

  22. Gilbert SC, Emmett M, Menter A, Silverman A, Klintmalm G (1989) Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol 21: 470–474

    Article  PubMed  CAS  Google Scholar 

  23. Gottlieb SL, Heftler NS, Gilleaudeau P, Johnson R, Vallat VP, Wolfe J, Gottlieb AB, Krueger JG (1995) Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study. J Am Acad Dermatol 33: 637–645

    Article  PubMed  CAS  Google Scholar 

  24. Griffiths CE, Powles AV, Baker BS, Fry L, Valdimarsson H (1988) Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis. Transplant Proc 20: 50–52

    PubMed  CAS  Google Scholar 

  25. Grossman RM, Delaney RJ, Brinton EA, Carter DM, Gottlieb AB (1991) Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 25: 648–651

    PubMed  CAS  Google Scholar 

  26. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la BM (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 31: 68–74

    PubMed  CAS  Google Scholar 

  27. Gubner R (1951) Effect of aminopterin on epithelial tissues. AMA. Arch Derm Syphilol 64: 688–699

    CAS  Google Scholar 

  28. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349: 658–665

    Article  PubMed  CAS  Google Scholar 

  29. Hiesse C, Larue JR, Kriaa F, Blanchet P, Bellamy J, Benoit G, Charpentier B (1995) Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 27: 2450–2451

    PubMed  CAS  Google Scholar 

  30. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, Beard A, Puvanarajan L, Paul C (2001) Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 44: 643–651

    Article  PubMed  CAS  Google Scholar 

  31. Jeffes EW III, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, Dang M, Voss K, Voss J, Schlotzhauer A (1995) Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 104: 183–188

    Article  PubMed  Google Scholar 

  32. Kirby B, Lyon CC, Griffiths CE, Chalmers RJ (2000) The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. Clin Exp Dermatol 25: 265–268

    Article  PubMed  CAS  Google Scholar 

  33. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE (2001) Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 26: 27–29

    Article  PubMed  CAS  Google Scholar 

  34. Kokelj F, Torsello P, Plozzer C (1998) Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 10: 143–146

    Article  PubMed  CAS  Google Scholar 

  35. Koo J (1999) Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 41: S25–S28

    Article  PubMed  CAS  Google Scholar 

  36. Kopp JB, Klotman PE (1990) Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1: 162–179

    PubMed  CAS  Google Scholar 

  37. Korstanje MJ, Breda Vriesman CJ, van de Staak WJ (1990) Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol 23: 320–321

    PubMed  CAS  Google Scholar 

  38. Korstanje MJ, van de Staak WJ (1990) Combinationtherapy cyclosporin-A — etretinate for psoriasis. Clin Exp Dermatol 15: 172–173

    Article  PubMed  CAS  Google Scholar 

  39. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME (1994) Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37: 316–328

    Article  PubMed  CAS  Google Scholar 

  40. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L (1994) Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 130: 366–375

    Article  PubMed  CAS  Google Scholar 

  41. Lanse SB, Arnold GL, Gowans JD, Kaplan MM (1985) Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio. Dig Dis Sci 30: 104–109

    Article  PubMed  CAS  Google Scholar 

  42. Lebwohl M, Ali S (2001) Treatment of psoriasis, part 2. Systemic therapies. J Am Acad Dermatol 45: 649–661

    Article  PubMed  CAS  Google Scholar 

  43. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP (1995) Risk of neoplasia in renal transplant patients. Lancet 346: 403–406

    Article  PubMed  CAS  ISI  Google Scholar 

  44. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, Bourget T, Dimov I, Simpson K, Glass E, Grabie MT (1996) Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 35: 710–719

    Article  PubMed  CAS  Google Scholar 

  45. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B (2003) CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 149: 170–173

    Article  PubMed  CAS  Google Scholar 

  46. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ (1996) Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 10: 369–375

    PubMed  CAS  Google Scholar 

  47. Marcil I, Stern RS (2001) Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358: 1042–1045

    Article  PubMed  CAS  ISI  Google Scholar 

  48. McClure SL, Valentine J, Gordon KB (2002) Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 25: 913–927

    Article  PubMed  CAS  ISI  Google Scholar 

  49. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385–390

    Article  PubMed  CAS  ISI  Google Scholar 

  50. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB (1982) Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 6: 46–51

    Article  PubMed  CAS  Google Scholar 

  51. Morris LF, Harrod MJ, Menter MA, Silverman AK (1993) Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 29: 913–916

    PubMed  CAS  Google Scholar 

  52. Mueller W, Herrmann B (1979) Cyclosporin A for psoriasis. N Engl J Med 301: 555

    PubMed  CAS  Google Scholar 

  53. Nyfors A (1977) Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand [A] 85: 511–518

    CAS  Google Scholar 

  54. Nyfors A (1978) Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull 25: 208–211

    PubMed  CAS  Google Scholar 

  55. Olsen EA (1991) The pharmacology of methotrexate. J Am Acad Dermatol 25: 306–318

    PubMed  CAS  Google Scholar 

  56. Paul C, Le Tourneau A, Cayuela JM, Devidas A, Robert C, Molinie V, Dubertret L (1997) Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 133: 867–871

    Article  PubMed  CAS  Google Scholar 

  57. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L (2003) Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120: 211–216

    Article  PubMed  CAS  Google Scholar 

  58. Petrazzuoli M, Rothe MJ, Grin-Jorgensen C, Ramsey WH, Grant-Kels JM (1994) Monitoring patients taking methotrexate for hepatotoxicity. Does the standard of care match published guidelines? J Am Acad Dermatol 31: 969–977

    Article  PubMed  CAS  Google Scholar 

  59. Petzelbauer P, Stingl G, Wolff K, Volc-Platzer B (1991) Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol 96: 362–369

    Article  PubMed  CAS  Google Scholar 

  60. Phillips TJ, Jones DH, Baker H (1987) Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 16: 373–375

    Article  PubMed  CAS  Google Scholar 

  61. Raman GV, Campbell SK, Farrer A, Albano JD, Cook J (1998) Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis. J Hypertens Suppl 16: S39–S41

    CAS  Google Scholar 

  62. Robinson JK, Baughman RD, Auerbach R, Cimis RJ (1980) Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 116: 413–415

    Article  PubMed  CAS  Google Scholar 

  63. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M (1998) Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38: 478–485

    Article  PubMed  Google Scholar 

  64. Roenigk HH Jr, Fowler-Bergfeld W, Curtis GH (1969) Methotrexate for psoriasis in weekly oral doses. Arch Dermatol 99: 86–93

    Article  PubMed  Google Scholar 

  65. Roenigk HH Jr, Maibach HI, Weinstein GP (1973) Methotrexate therapy for psoriasis. Guideline revisions. Arch Dermatol 108: 35

    Article  PubMed  Google Scholar 

  66. Ruiz P, Kolbeck PC, Scroggs MW, Bollinger RR, Sanfilippo F (1988) Cyclosporine therapy and the development of interstitial fibrosis in renal allografts. Transplant Proc 20: 807–811

    PubMed  CAS  Google Scholar 

  67. Shupack J, Abel E, Bauer E, Brown M, Drake L, Freinkel R, Guzzo C, Koo J, Levine N, Lowe N, McDonald C, Margolis D, Stiller M, Wintroub B, Bainbridge C, Evans S, Hilss S, Mietlowski W, Winslow C, Birnbaum JE (1997) Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 36: 423–432

    Article  PubMed  CAS  Google Scholar 

  68. Stern RS, Laird N (1994) The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 73: 2759–2764

    Article  PubMed  CAS  ISI  Google Scholar 

  69. Stiller MJ, Pak GH, Kenny C, Jondreau L, Davis I, Wachsman S, Shupack JL (1992) Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol 27: 434–438

    PubMed  CAS  Google Scholar 

  70. Sussman A, Leonard JM (1980) Psoriasis, methotrexate, and oligospermia. Arch Dermatol 116: 215–217

    Article  PubMed  CAS  Google Scholar 

  71. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC (1992) The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 42: 121–125

    Article  PubMed  CAS  Google Scholar 

  72. Weinstein GD, Frost P (1971) Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 103: 33–38

    Article  PubMed  CAS  Google Scholar 

  73. Weinstein GD, Velasco J (1972) Selective action of methotrexate on psoriatic epidermal cells. J Invest Dermatol 59: 121–127

    Article  PubMed  CAS  Google Scholar 

  74. Whiting-O’Keefe QE, Fye KH, Sack KD ((1991) Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90: 711–716

    PubMed  CAS  Google Scholar 

  75. Zachariae H (1990) Methotrexate side-effects. Br J Dermatol 122Suppl 36: 127–133

    Article  PubMed  Google Scholar 

  76. Zachariae H, Grunnet E, Sogaard H (1975) Liver biopsy in methotrexate-treated psoriatics — a re-evaluation. Acta Derm Venereol 55: 291–296

    PubMed  CAS  Google Scholar 

  77. Zachariae H, Heickendorff L, Sogaard H (2001) The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 144: 100–103

    Article  PubMed  CAS  Google Scholar 

  78. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S (1997) Renal biopsy findings in longterm cyclosporin treatment of psoriasis. Br J Dermatol 136: 531–535

    Article  PubMed  CAS  Google Scholar 

  79. Zachariae H, Sogaard H (1987) Methotrexate-induced liver cirrhosis. A follow-up. Dermatologica 175: 178–182

    PubMed  CAS  ISI  Google Scholar 

  80. Zachariae H, Sogaard H, Heickendorff L (1996) Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies — a further 10-year follow-up. Dermatology 192: 343–346

    Article  PubMed  CAS  ISI  Google Scholar 

  81. Zackheim HS, Koo J, LeBoit PE, McCalmont TH, Bowman PH, Kashani-Sabet M, Jones C, Zehnder J (2002) Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. J Am Acad Dermatol 47: 155–157

    Article  PubMed  Google Scholar 

Download references

Editor information

Editors and Affiliations

  1. Division of Dermatology, Loyola University, Stritch School of Medicine, 2160 S. First Ave., Building 112, Room 342, Maywood, IL, 60153, USA

    Kenneth B. Gordon MD

  2. Division of Rheumatology, Northwestern University, Feinberg School of Medicine, 675 N. St. Clair St., Chicago, IL, 60611, USA

    Eric M. Ruderman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

(2005). Psoriasis. In: Gordon, K.B., Ruderman, E.M. (eds) Psoriasis and Psoriatic Arthritis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27190-2_16

Download citation

  • DOI: https://doi.org/10.1007/3-540-27190-2_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21280-5

  • Online ISBN: 978-3-540-27190-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation